Scalper1 News
Specialty-drug maker Mallinckrodt (MNK) reported mixed fiscal Q1 results Tuesday, sending the stock down as much as 6%. In the quarter ended Dec. 26, Mallinckrodt’s earnings excluding one-time items more than doubled over the year-earlier quarter to $1.84 a share, beating analysts’ consensus by 26 cents. Sales rose 60% to $866.3 million, about $20 million short of the Street’s average estimate. The company didn’t offer any new guidance, but on the Scalper1 News
Scalper1 News